comparemela.com

Latest Breaking News On - Cello healthcare - Page 1 : comparemela.com

Helix Biopharma Corp Announces Fiscal 2022 Second Quarter Results

16.03.2022 - RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), ( Helix or the Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary .

Richmond hillFrank michalargiasSlawomir majewskiToronto stock exchangeCompany statements of financial positionDrug administrationHelix biopharma corpCompany interim condensed financialBoard of directors the companyIncentive programInterim chief executive officerInterim chief executiveChief executiveCello healthcareConsulting managementFinancial position

Helix BioPharma Corp : Helix Biopharma Corp Announces Fiscal 2022 Second Quarter Results

RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology

Richmond hillFrank michalargiasSlawomir majewskiToronto stock exchangeCompany statements of financial positionDrug administrationHelix biopharma corpCompany interim condensed financialBoard of directors the companyIncentive programHelix biopharmaInterim chief executive officerChief executiveCello healthcareConsulting managementFinancial position

Helix BioPharma Corp Provides Corporate Update

RICHMOND HILL, ON / ACCESSWIRE / December 31, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and

Richmond hillFrank michalargiasSlawomir majewskiChristof boehlerCompany phaseToronto stock exchangeHelix biopharma corpLind global macro fundHelix biopharmaCello healthcareAtul deshpandeChief financialLooking statementsChief executiveAnnual filingsAnnual information form

Helix BioPharma Corp says 2021 a productive year as it anticipates results of its Phase I and II studies in lung cancer in 2022

During the second half of 2021, the company initiated efforts to validate Helix and its lead clinical program with external stakeholders to.

Slawomir majewskiChristof boehlerRichmond hillHelix biopharma corpLind global macro fundCello healthcareAtul deshpande

vimarsana © 2020. All Rights Reserved.